Shiotsuka Yuki, Uebuchi Miki, Hamada Seiji, Morita Naofumi, Moriyama Akira, Yamashita Mayuko, Ichikawa Yasuko, Fujii Hiroshi, Matsuo Akinobu, Kuhara Hiroshi, Ikuta Yoshiaki, Ikeshima Satoshi, Kuramoto Masafumi, Fujii Kenichiro, Shimada Shinya
Dept. of Pharmacy, Yatsushiro Social Insurance General Hospital, Japan.
Gan To Kagaku Ryoho. 2012 Oct;39(10):1583-6.
Seven patients who had been receiving capecitabine+oxaliplatin±bevacizumab(CapeOX±BV)therapy at our hospital between February 2010 and March 2011, had complained of angialgia during oxaliplatin(L-OHP)administration. Therefore, 3. 3 mg of dexamethasone(DEX)was added to their infusion solution. The patients were then asked to rate their angialgia severity using a numerical rating scale(NRS), when L-OHP in a 5% dextrose solution was administered with or without DEX. By changing the L-OHP in 5% dextrose solution without DEX to the solution containing 3. 3 mg of DEX, the mean NRS was improved to 2. 4 from 7. 1. These findings indicate that L-OHP in 5% dextrose solution mixed with 3. 3 mg of DEX seems to be useful in reducing angialgia during peripheral administration of L-OHP.
